Abstract
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in about 3% to 7% of patients with non–small cell lung cancer (NSCLC) and are the key drivers of cancer cell proliferation in ALK-positive NSCLC. ALK tyrosine kinase inhibitors (TKIs) are potent oral inhibitors of the abnormal ALK protein and are standard first-line treatments for patients with ALK-positive metastatic NSCLC (mNSCLC). Lorlatinib is a brain-penetrant, third-generation ALK TKI that was approved by the US Food and Drug Administration in 2018 for the second- or third-line treatment of patients with ALK-positive mNSCLC and in 2021 for first-line treatment, based on the results of the phase III CROWN study (NCT03052608). The recent 5-year results of the CROWN study showed that median progression-free survival had yet to be reached in the lorlatinib group, corresponding to the longest progression-free survival reported with any single-agent molecular targeted treatment in advanced NSCLC and all metastatic solid tumors (Solomon et al., 2024). These results, along with the extended intracranial efficacy and consistent safety profile of long-term lorlatinib treatment, are unprecedented in patients with ALK-positive mNSCLC. This Grand Rounds article summarizes the efficacy, safety, and tolerability of lorlatinib after 5 years and includes a fictional patient case to demonstrate how advanced practice providers contribute to personalized patient care and the identification and management of adverse events.
References
Alonso, R., Cuevas, A., & Cafferata, A. (2019). Diagnosis and management of statin intolerance. Journal of Atherosclerosis and Thrombosis, 26(3), 207–215. https://doi.org/10.5551/jat.RV17030
Bauer, T. M., & Bertino, E. M. (2022). Podcast on the management of adverse events associated with lorlatinib. Advances in Therapy, 39(4), 1447–1456. https://doi.org/10.1007/s12325-022-02050-3
Bauer, T. M., Felip, E., Solomon, B. J., Thurm, H., Peltz, G., Chioda, M. D., & Shaw, A. T. (2019). Clinical management of adverse events associated with lorlatinib. The Oncologist, 24(8), 1103–1110. https://doi.org/10.1634/theoncologist.2018-0380
Bauman, J. R., Liu, G., Preeshagul, I., Liu, S. V., Melosky, B., Abrahami, D., Li, B., Thomaidou, D., Duncan, K., Krulewicz, S., Rupp, M., & Lin, J. J. (2024). Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer. Lung Cancer, 195, 107919. https://doi.org/10.1016/j.lungcan.2024.107919
Bazhenova, L., Abrahami, D., Ramaswamy, K., Li, B., Davis, M., Epstein, A. J., Marcum, Z. A., Rifi, N., Kelton, J., Duncan, K., & Uprety, D. (2024). EP.17A.01 The cumulative incidence of brain metastases in US Medicare patients with ALK+ mNSCLC treated with second-generation ALK TKIs. Journal of Thoracic Oncology, 19(10), S711–S712. https://doi.org/10.1016/j.jtho.2024.09.1352
Blackhall, F., & Cappuzzo, F. (2016). Crizotinib: from discovery to accelerated development to front-line treatment. Annals of Oncology, 27, iii35–iii41. https://doi.org/10.1093/annonc/mdw304
Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C., Han, J. Y., Lee, J. S., Hochmair, M. J., Li, J. Y., Chang, G. C., Lee, K. H., Gridelli, C., Delmonte, A., Garcia Campelo, R., Kim, D. W., Bearz, A., Griesinger, F., Morabito, A., Felip, E., Califano, R.,…Popat, S. (2018). Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. The New England Journal of Medicine, 379(21), 2027–2039. https://doi.org/10.1056/NEJMoa1810171
Chen, J., Bearz, A., Kim, D. W., Mamdani, H., Bauman, J., Chiari, R., Ou, S. I., Solomon, B. J., Soo, R. A., Felip, E., Shaw, A. T., Thurm, H., Clancy, J. S., Lee, K., O’Gorman, M., Tanski, C., & Pithavala, Y. K. (2024). Evaluation of the effect of lorlatinib on CYP2B6, CYP2C9, UGT, and P-glycoprotein substrates in patients with advanced non–small cell lung cancer. Clinical Pharmacokinetics, 63(2), 171–182. https://doi.org/10.1007/s40262-023-01309-4
Dorababu, M., Nishimura, A., Prabha, T., Naruhashi, K., Sugioka, N., Takada, K., & Shibata, N. (2009). Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomedicine & Pharmacotherapy, 63(9), 697–702. https://doi.org/10.1016/j.biopha.2009.04.031
Fox Chase Cancer Center. (2014). FDA approves novartis drug Zykadia™ for late-stage lung cancer. https://www.foxchase.org/news/fda-approves-novartis-drug-zykadia%E2%84%A2-late-stage-lung-cancer
Fung, W. T., Subramaniam, G., Lee, J., Loh, H. M., & Leung, P. H. H. (2012). Assessment of extracts from red yeast rice for herb-drug interaction by in-vitro and in-vivo assays. Scientific Reports, 2(1), 298. https://doi.org/10.1038/srep00298
Gafer, H., de Waard, Q., Compter, A., & van den Heuvel, M. (2019). Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases. BMJ Case Reports, 12(7), e227299. https://doi.org/10.1136/bcr-2018-227299
Genentech. (2015). FDA grants Genentech’s Alecensa® (alectinib) accelerated approval for people with a specific type of lung cancer. https://www.gene.com/media/press-releases/14615/2015-12-11/fda-grants-genentechs-alecensa-alectinib
Gulikers, J. L., Slikkerveer, M., Winckers, K., Hendriks, L. E. L., Dursun, S., Croes, S., & van Geel, R. M. J. M. (2022). Case report: drug-drug interaction between alectinib and apixaban in NSCLC. Current Problems in Cancer: Case Reports, 7, 100186. https://doi.org/10.1016/j.cpccr.2022.100186
Guo, Y., Guo, H., Zhang, Y., & Cui, J. (2022). Anaplastic lymphoma kinase-special immunity and immunotherapy. Frontiers in Immunology, 13, 908894. https://doi.org/10.3389/fimmu.2022.908894
Hirsch, F. R., & Kim, C. (2024). The importance of biomarker testing in the treatment of advanced non-small cell lung cancer: a podcast. Oncology and Therapy, 12(2), 223–231. https://doi.org/10.1007/s40487-024-00271-w
Kane, G. C., & Lipsky, J. J. (2000). Drug-grapefruit juice interactions. Mayo Clinic Proceedings, 75(9), 933–942. https://doi.org/10.4065/75.9.933
Liu, G., Mazieres, J., Stratmann, J., Ou, S. I., Mok, T., Grizzard, M., Goto, Y., Felip, E., Solomon, B. J., & Bauer, T. M. (2024). A pragmatic guide for management of adverse events associated with lorlatinib. Lung Cancer, 191, 107535. https://doi.org/10.1016/j.lungcan.2024.107535
Malik, S. M., Maher, V. E., Bijwaard, K. E., Becker, R. L., Zhang, L., Tang, S. W., Song, P., Liu, Q., Marathe, A., Gehrke, B., Helms, W., Hanner, D., Justice, R., & Pazdur, R. (2014). U.S. Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clinical Cancer Research, 20(8), 2029–2034. https://doi.org/10.1158/1078-0432.Ccr-13-3077
Marok, F. Z., Wojtyniak, J. G., Fuhr, L. M., Selzer, D., Schwab, M., Weiss, J., Haefeli, W. E., & Lehr, T. (2023). A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug-drug interaction perpetrators. Pharmaceutics, 15(2). https://doi.org/10.3390/pharmaceutics15020679
Murakami, Y., Kawashima, Y., Chiba, S., Hara, S., Yamazaki, Y., Doman, T., Saito, S., Odaka, T., Ogasawara, T., Shimizu, H., Sugisaka, J., Aiba, T., Toi, Y., Yamanda, S., Kimura, Y., & Sugawara, S. (2024). Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases. Cancer Reports, 7(2), e1981. https://doi.org/10.1002/cnr2.1981
Novartis Pharmaceuticals Corporation. (2021). ZYKADIA® (ceritinib) prescribing information. In: Novartis Pharmaceuticals Corporation.
Pfizer. (2011). U.S. Food And Drug Administration approves Pfizer’s XALKORI® (crizotinib) as first and only therapy specifically for patients with locally advanced or metastatic ALK-positive non-small cell lung cancer. https://www.pfizer.com/news/press-release/press-release-detail/u_s_food_and_drug_administration_approves_pfizer_s_xalkori_crizotinib_as_first_and_only_therapy_specifically_for_patients_with_locally_advanced_or_metastatic_alk_positive_non_small_cell_lung_cancer
Pfizer. (2018). FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC. https://www.fda.gov/drugs/fda-approves-lorlatinib-second-or-third-line-treatment-alk-positive-metastatic-nsclc
Pfizer. (2021). FDA approves lorlatinib for metastatic ALK-positive NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc
Pfizer Labs. (2023). LORBRENA® (lorlatinib) prescribing information. New York, NY, USA.
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E., Mahadevan, A., Floyd, S. R., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., & Costa, D. B. (2015). Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer, 88(1), 108–111. https://doi.org/10.1016/j.lungcan.2015.01.020
Reed, M., Rosales, A. S., Chioda, M. D., Parker, L., Devgan, G., & Kettle, J. (2020). Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. Advances in Therapy, 37(6), 3019–3030. https://doi.org/10.1007/s12325-020-01365-3
Riechelmann, R. P., & Del Giglio, A. (2009). Drug interactions in oncology: how common are they? Annals of Oncology, 20(12), 1907–1912. https://doi.org/10.1093/annonc/mdp369
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., DeCamp, M., Desai, A. P., Dilling, T. J., Dowell, J., Durm, G. A., Gettinger, S., Grotz, T. E., Gubens, M. A., Juloori, A.,…Hang, L. (2024). Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 22(4), 249–274. https://doi.org/10.6004/jnccn.2204.0023
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D. W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., & Solomon, B. J. (2020). First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. The New England Journal of Medicine, 383(21), 2018–2029. https://doi.org/10.1056/NEJMoa2027187
Solomon, B. J., Liu, G., Felip, E., Mok, T. S. K., Soo, R. A., Mazieres, J., Shaw, A. T., de Marinis, F., Goto, Y., Wu, Y. L., Kim, D. W., Martini, J. F., Messina, R., Paolini, J., Polli, A., Thomaidou, D., Toffalorio, F., & Bauer, T. M. (2024). Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. Journal of Clinical Oncology, 42(29), 3400–3409. https://doi.org/10.1200/jco.24.00581
Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K. D., Tursi, J., & Blackhall, F. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine, 371(23), 2167–2177. https://doi.org/10.1056/NEJMoa1408440
UpToDate. (2025). Cytochrome P450 3A (including 3A4) inhibitors and inducers UpToDate, Inc. https://www.uptodate.com/contents/image?imageKey=CARD/76992
US Food and Drug Administration. (2017a). Alectinib approved for (ALK) positive metastatic non-small cell lung cancer (NSCLC). https://www.fda.gov/drugs/resources-information-approved-drugs/alectinib-approved-alk-positive-metastatic-non-small-cell-lung-cancer-nsclc
US Food and Drug Administration. (2017b). Brigatinib. https://www.fda.gov/drugs/resources-information-approved-drugs/brigatinib
US Food and Drug Administration. (2017c). FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-ceritinib-indication-previously-untreated-alk-positive-metastatic-nsclc
US Food and Drug Administration. (2020). FDA approves brigatinib for ALK-positive metastatic NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc
US Food and Drug Administration. (2024). FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ensartinib-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer
Wang, E. J., Lew, K., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2002). Interaction of common azole antifungals with P glycoprotein. Antimicrobial Agents and Chemotherapy, 46(1), 160–165. https://doi.org/10.1128/aac.46.1.160-165.2002
Wang, X., Romero-Gutierrez, C. W., Kothari, J., Shafer, A., Li, Y., & Christiani, D. C. (2023). Prediagnosis smoking cessation and overall survival among patients with non-small cell lung cancer. JAMA Network Open, 6(5), e2311966. https://doi.org/10.1001/jamanetworkopen.2023.11966
Wei, J., Zhou, H., & Song, Z. (2023). Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study. Journal of Thoracic Disease, 15(5), 2425–2437. https://doi.org/10.21037/jtd-22-1783
Wessler, J. D., Grip, L. T., Mendell, J., & Giugliano, R. P. (2013). The P-glycoprotein transport system and cardiovascular drugs. Journal of the American College of Cardiology, 61(25), 2495–2502. https://doi.org/10.1016/j.jacc.2013.02.058
Wu, J., Savooji, J., & Liu, D. (2016). Second- and third-generation ALK inhibitors for non-small cell lung cancer. Journal of Hematology & Oncology, 9(1), 19. https://doi.org/10.1186/s13045-016-0251-8
